Chao Xue

Chao Xue

Auto-generated profile, based on publicly available information

Chao Xue

Proteomics & Bioanalysis Lab, New York State Center of Excellence in Bioinformatics and Life Sciences, Buffalo (M.M., C.X., M.Z., J.Q.).

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2026 in Circulation Research
Verified
Journal Article
Closed access
MMMin Ma
Min Ma
YLYingyi Lian
Yingyi Lian
ESErfei Shang
Erfei Shang
CXChao Xue
Chao Xue
MWMaosheng Wei
Maosheng Wei
Jun  QuJun Qu
Jun Qu
Cardiovascular function is tightly linked to tissue architectures, where the spatial organization of cells, extracellular matrix (ECM), vascular networks, and remodeling processes governs physiological performance and disease progression. Spatial proteomics has, therefore, emerged as a powerful framework for understanding cardiovascular biology and cardiovascular disease mechanisms by revealing spatially organized protein regulation across various physiological and pathological states. In this review, we focus on spatial proteomics strategies most relevant to cardiovascular research and discuss their applications through representative examples. These approaches can be broadly categorized into region-of-interest–based methods, which enable precise characterization of localized cellular heterogeneity, and tissue mapping strategies, which capture spatial organization and biologically relevant region-to-region variability across larger tissue domains. In addition, spatial proteomics platforms differ in their capacity for targeted or untargeted protein analysis, influencing both proteome coverage and their suitability for hypothesis-driven versus discovery-based studies. We evaluate the strengths and limitations of state-of-the-art technologies across 3 key parameters, molecular depth, spatial coverage, and spatial resolution, and discuss how these parameters shape study design and biological understanding. Building on these considerations, we argue that a comprehensive understanding of cardiovascular tissue biology requires spatial proteomics strategies that capture both localized molecular details and spatial organization across large tissue areas, as neither alone is sufficient to explain complex tissue behavior. We propose an integrated workflow in which untargeted, whole-tissue mapping of thousands of proteins is first used to unbiasedly discover spatial patterns and generate hypotheses by identifying candidate regions and proteins of interest, followed by hypothesis testing and validation using high-precision region-of-interest–based proteomics and targeted protein imaging. This sequential framework leverages the complementary strengths of tissue-wide mapping and region-of-interest–based approaches to provide multiscale, mechanistic insights into spatially organized disease processes. Finally, we discuss emerging directions that are poised to expand the scope of spatial proteomics in cardiovascular research.

13 January 2026 in Cancer Research
Verified
Journal Article
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
Reprogramming of the androgen receptor (AR) cistrome is associated with prostate cancer progression, and advanced castration-resistant prostate cancers (CRPC) tend to rely on reprogrammed/noncanonical AR signaling that remains active under treatment with AR signaling inhibitors (ARSI). In this study, we identified ecotropic viral integration site 1 (EVI1), an oncogenic nuclear transcription factor (TF) encoded by MECOM, as an AR-recruited coactivator of noncanonical signaling. In prostate cancer, MECOM was exclusively overexpressed in both CRPC and enzalutamide-resistant CRPC and interacted with AR in the nucleus. MECOM depletion in prostate cancer cells decreased proliferation, altered cell survival transcriptional programs, and reduced the number of super-enhancers (SE), leading to a dynamic change in the SE landscape and a decrease in the expression of SE-regulated oncogenic TFs, along with increased proapoptotic signatures. Notably, cells overexpressing MECOM and its protein, EVI1, were susceptible to PARP inhibitors (PARPi) regardless of their DNA damage response or homologous recombination repair (HRR) gene mutation status. These insights reveal the crucial role of EVI1 in regulating cell survival within the context of an AR-reprogrammed chromatin landscape. More importantly, the findings suggest that MECOM overexpression may be another biomarker that could significantly broaden the use of PARPis beyond those with HRR gene mutations. Significance: MECOM is a driver of androgen receptor inhibitor resistance in castrate-resistant prostate cancer that promotes susceptibility to PARP inhibition, positioning MECOM as a biomarker in patients without homologous recombination repair gene mutations.

17 June 2026
Verified
Other
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
Functional studies confers the role of MECOM in regulation of AR activity and survival transcriptional programs

17 June 2026
Verified
Other
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
MECOM expression increases with disease progression and treatment-resistance in PCa

17 June 2026
Verified
Other
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
Functional suppression of MECOM alters AR binding and H3K27ac enrichment in CRPC cell lines

17 June 2026
Verified
Other
Open access
SGSURENDRA GULLA
SURENDRA GULLA
TSTej sharma
Tej sharma
EGEphraim Gardner
Ephraim Gardner
CLChennan Li
Chennan Li
TPTanaya A. Purohit
Tanaya A. Purohit
RARemi Adelaiye-Ogala
Remi Adelaiye-Ogala
PARP inhibitors in combination with enzalutamide suppress MECOM and AR expression, suppress proliferation, and increase apoptosis in enzalutamide-resistant CRPC